Marquis Who's Who Recognizes Steven M. Stanley for Expertise in Paleontology
'Writing this novel was a way to engage with a broader audience and share the excitement of discovery that has driven my career in paleontology,' Dr. Stanley explains. His previous works, such as 'Children of the Ice Age' and 'The New Evolutionary Timetable,' have been lauded for their depth and accessibility, with 'The New Evolutionary Timetable' earning a nomination for an American Book Award.
Dr. Stanley's passion for science began early in life. Growing up on 24 acres of river land, he developed an interest in collecting rocks and minerals, which later led him to study geology at Princeton University, where he graduated summa cum laude. He went on to earn a PhD from Yale University in 1968. His doctoral dissertation, 'Relation of Shell Form to Life Habits in the Bivalvia (Mollusca),' remains a seminal work in the study of skeletal morphology and continues to be cited nearly 50 years after its publication.
At age eight, 'The First Book of Stones' motivated Dr. Stanley to collect rocks and minerals. At 15, a famous medical researcher invited him for a month of mineral collecting in Colorado. The next summer, he collected minerals in northern Michigan. Dr. Stanley became the youngest full professor at Johns Hopkins University at 32 years old, where he founded and chaired a part-time evening master's program in environmental sciences and policy. Since 1972, he has been a research associate at the Smithsonian Institution, where he maintains a laboratory for ongoing research.
In 'T. Rex, Darwin and Adventures Out West,' Dr. Stanley weaves a narrative rich in scientific detail and human drama. The story, which at one point becomes a mystery, follows a group of college students and their professors on a journey that challenges their understanding of the world around them. 'The novel allowed me to explore themes of adventure, discovery and the bonds that form through shared experiences,' he adds.
Dr. Stanley is renowned for his contributions to evolutionary biology, particularly his work on the theory of punctuated equilibria and the magnesium/calcium ratio in seawater. These studies have significantly advanced the understanding of marine life's history and evolutionary processes.
Dr. Stanley's textbook 'Principles of Paleontology,' co-authored with David Raup, transformed paleontology education in the U.S. and abroad. His historical geology text 'Earth System History,' now in its seventh edition, has been used by approximately half a million students.
Dr. Stanley's work has earned him numerous accolades, including the Penrose Medal, which is the highest award of the Geological Society of America, for eminence in pure research, and the Mary Clark Thompson Medal from the National Academy of Sciences. His influential book, 'Macroevolution: Pattern and Process,' remains widely cited in both biology and paleontology. Dr. Stanley attributes his success to deductive reasoning, creativity and a willingness to embrace controversy.
In 'T. Rex, Darwin and Adventures Out West,' Dr. Stanley's unique perspective as a scientist and storyteller shines through, making it a must-read for anyone interested in the intersection of science and literature. Looking ahead, Dr. Stanley plans to write another textbook.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms worldwide. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Alligator Bioscience to Host Virtual R&D Day on 19 August 2025
LUND, SE / / August 14, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announces that it will host a virtual R&D Day on Tuesday, 19 August 2025 at 4 p.m. CEST. The event will provide an in-depth update on Alligator's R&D pipeline, with a primary focus on its lead candidate mitazalimab, ahead of the upcoming TO 13 warrant exercise period (1-15 September 2025). During the event, members of Alligator's executive management and R&D leadership will: Provide update on mitazalimab clinical data, as well biomarker findings and Phase 3 readiness. Discuss ongoing and planned investigator-initiated trials (IITs) exploring mitazalimab in additional indications and clinical settings. Provide a brief update on the pipeline program HLX22. Outline key R&D milestones over the next 6-12 months. The R&D Day will be held as a live Teams webinar and will include a Q&A session. All participants will have the opportunity to submit questions in advance, via ir@ or during the event. Event detailsDate: Tuesday, 19 August 2025Time: 4-5 p.m. CESTFormat: Virtual Teams webinarRegistration: Please use this link to register A replay of the event will be made available on Alligator's website after the webinar. For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 1:00 p.m. CEST on 14 August 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit Attachments Alligator Bioscience to host virtual R&D Day on 19 August 2025 SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
3 days ago
- Yahoo
I'm a physicist who studies fossils, and I recently discovered preserved blood vessels in the world's largest T. rex
Despite the fact that much of the current research in paleontology focuses on trying to find traces of organic remains in fossils, dinosaur DNA has unfortunately never been recovered. A lot of what we know about dinosaurs comes from preserved bones and teeth that are dug out of the ground. These hard tissues alone, however, are limited in the information they provide. Soft tissues are extremely rare in the fossil record, but can help provide a much more life-like reconstruction of ancient life. This includes things like muscles and ligaments, pigments or even skin (like scales or feathers), which contain detailed information on how dinosaurs lived and what they looked like. Another interesting soft tissue that can be found in bones are blood vessels. My research team and I discovered blood vessels preserved in a Tyrannosaurus rex fossil, and our findings were recently published in Scientific Reports. As an undergraduate physics student at the University of Regina, I joined a research team using particle accelerators to study fossils. There, I first discovered blood vessels in a bone from a T. rex using advanced 3D models. It's been nearly six years since that moment; I am now working on my PhD where I use my background in physics to advance analysis techniques in fossil research. An extraordinary specimen The vessels were found in a remarkable T. rex specimen nicknamed Scotty. Held in the Royal Saskatchewan Museum's collection in Canada, Scotty is the largest T. rex ever unearthed. The fossil also remains one of the most complete specimens of T. rex. Scotty appeared to have had a rough life 66 million years ago; many of the recovered bones appeared to have injuries, possibly due to a fight with another dinosaur, or disease. One bone in particular, a section of rib, features a large partially healed fracture. In general, after bones experience a traumatic event like a fracture, there is a huge increase in the activity of blood vessels in the affected area as part of the healing process. We believe this is what was found in Scotty's rib: an extensive network of mineralized vessels that we were able to examine using reconstructed 3D models. Revolutionizing paleontology research When analyzing fossil bones, there are two main challenges. The first is how to examine the interior of the bones without damaging the fossil. And second, the bones are very large and can be quite dense due to the fossilization process, where minerals replace and fill in original organic materials. At first, we thought we could perform an computed topography (CT) scan of the bone, similar to what is used for medical purposes, which allows imaging of bones without damaging them. While this solves the first problem, the second problem means that a conventional medical CT machine is not nearly powerful enough to penetrate the dense bone. For our examination, we used synchrotron light, special high-intensity x-rays. These are produced at select particle accelerator labs, and allow us to investigate microstructures such as blood vessels in the bone with ease. Synchrotron x-rays can also be useful for chemical analysis. We found the vessels were preserved as iron-rich mineralized casts, a common form of fossilization, but in two distinct layers. This layering is due to the complicated environmental history that led to the exceptional preservation seen in Scotty's rib. Written in blood vessels By analyzing blood vessels produced by an incompletely healed fracture, we can hopefully learn how T. rex healed, helping speculation on how Scotty was able to survive after sustaining injuries. This could lead to evolutionary information comparing the vessel structures seen in Scotty to other dinosaur species, as well as modern relatives to dinosaurs like birds. The results may also help future fossil exploration by guiding scientists to target bones that show signs of injury or disease, potentially increasing the chances of discovering more vessels or other types of preserved soft tissues. With cross-disciplinary research and novel applications of advanced technologies, there is so much potential to recreate the past lives of dinosaurs like never before. This article is republished from The Conversation, a nonprofit, independent news organisation bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Jerit Leo Mitchell, University of Regina Read more: An exquisitely preserved egg reveals what birds have inherited from dinosaurs Thirty years after Jurassic Park hit movie screens, its impact on science and culture remains as strong as ever – podcast Big head, small arms: A newly discovered gigantic dinosaur evolved in a similar manner to Tyrannosaurus rex Jerit Leo Mitchell receives funding from Mitacs Accelerate and the Sylvia Fedoruk Centre for Nuclear Innovation.
Indianapolis Star
6 days ago
- Indianapolis Star
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
SHELTON, CT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union. NV-387 is possibly the only drug candidate that has been shown to be effective and safe in animal model studies of Measles virus in humanized h-CD150+ knock-in mice, as reported previously by NanoViricides. NV-387 has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans. The development of NV-387 as a treatment for Measles can be accelerated under the US FDA programs. Measles is considered a rare orphan disease in the USA. As such, NV-387 for the treatment of Measles would qualify for an Orphan Drug Designation. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval [1]. The Company also plans to explore a 'Fast Track' designation for the NV-387 Measles indication. If granted, a drug approval can occur on the basis of a successful Phase II clinical trial without requiring a Phase III clinical trial, which significantly reduces the timeline to approval. Measles has become an important disease of concern globally in the recent years for several reasons. Most importantly, Measles disease can wipe out the previously learned immunity of the patient against many infections, including from prior infections, and non-live virus vaccines, making the population vulnerable to viruses that were encountered previously. This is because Measles virus attacks the CD150-bearing immune cells that are responsible for memorizing the prior infections and mounting defenses against them later. Measles is possibly the most communicable diseases, spreading through aerosol, that is known to humans. In patients, it produces severe morbidity with skin rash, pain, fatigue, and other syndromes. Rarely it can cause a brain disease. Measles mostly affects children. There were a total of 1,319 confirmed measles cases reported in the USA as of July 22, breaking the most recent record of 1,274 cases in 2019. Hospitalization rates for measles in the USA are about 13%, and fatalities are rare, although in 2025 there were three deaths to date. Canada is having a much worse Measles season than the USA, with more than 3,800 cases [2] to date in 2025. A Measles holiday warning has been issued in the UK this year [3]. England itself had more than 3,000 cases of Measles in 2024. In the European Region, 127,350 measles cases were reported for 2024, double the number of cases reported for 2023 and the highest number since 1997, according to an analysis by WHO and the United Nations Children's Fund (UNICEF) [4]. Worldwide, Measles cases continue to occur every year. Globally, there have been about 108,000 confirmed measles cases in 2025 to date, while in 2024 there were about 360,000 confirmed cases, according to the WHO [5]. A sustained measles vaccination rate of at least 95% is estimated to be required to maintain community immunity ('herd immunity'). Such a high rate is becoming increasingly difficult to achieve even in developed countries where access to vaccination is not an issue. While growing vaccine hesitancy is considered an important reason for the fall in Measles vaccination rates, two other factors are of importance as well: (i) The overall population in the industrialized world, as well as in developing world, has increased frequency of immune dysfunction, obesity, and diabetes. The people with immune dysfunction or immune compromise are less likely to benefit from almost any standard vaccination as compared to healthy people and are likely to result in breakthrough infections. (ii) Additionally, the current vaccine for Measles is a live attenuated vaccine of the 1968 era, and the virus has evolved well past that, although so far the Measles virus strains continue to be susceptible to antibodies produced from the standard vaccine; this can change with continuing circulation of the virus in vaccinated persons and can result in a virus that can substantially defeat the vaccine [6]. Further, vaccine hesitancy itself is not irrational because the standard Measles vaccine is a live attenuated vaccine to be given to infants at early age; it is a virus infection that continues to remain in the subject, which is why it provides lifelong immunity. Measles infection itself also provides lifelong immunity that includes the current strains of the virus. Thus, the Company projects continuing Measles cases worldwide, that require a drug to control the disease in the patient and its spread to others. We believe NV-387 fills this important medical need. There is no approved drug for treatment of Measles at present. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ View the original press release on ACCESS Newswire The post Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides appeared first on DA80 Hub.
